AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV

Recruitingn/aAges 18 Years - anyAllAssistance Publique - Hôpitaux de Paris
💬

In plain words

What the trial is, and whether it could suit you

A short description, 5000 characters Intro: Respiratory Syncytial Virus (RSV) is a frequent, ubiquitous agent of respiratory viral infections. It is the leading viral cause of lower respiratory tract infection (LRTI) in infants and also causes significant morbidity and mortality in adults, especially in the elderly, in patients with cardiorespiratory comorbidities \[e.g., patients with Chronic Obstructive Pulmonary Disease (COPD) and/or heart failure\], and in immunocompromised patients. Clinical phenotyping of RSV respiratory infections has shown that the occurrence of LRTI in RSV-infected patients is associated with the need for ventilatory support and an increased risk of mortality. Virological data also suggest that there is a relationship between high nasopharyngeal viral replication levels and a poor prognosis, although these data have not been confirmed in other studies. Beyond vi

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Group of patients with RSV diagnosis Inclusion Criteria: * Age \> 18 years * Positive RSV RT-PCR in nasopharyngeal swab * Patient admitted to the hospital (intensive care unit or medical ward admission at inclusion) with clinical signs of lower respiratory tract infection (defined as the presence of two or more respiratory signes (cough, dyspnea, sputum production, wheezing, tachypnea (respiratory rate\>20/min) or one respiratory sign plus one or more systemic symptoms (fatigue and fever)) requiring hospitalization. * No objection letter (from the patient or a member of family if the patient is not physically able to give consent Exclusion Criteria: * Co-infection with other respiratory viruses * Persons under guardianship/guardianship * AME (state medical aid) patient Group of "control" patients Inclusion Criteria : * Age\>18 years * Patient's consent * Enrolled in a social security plan * Admitted for an acute respiratory syndrome * No diagnosis of respiratory infection in the 4 weeks prior to inclusion * Negative RSV nasopharyngeal PCR (or other respiratory specimen) collected within the last 48 hours * No immunosuppression (HIV infection, bone marrow or solid organ transplantation, post-chemotherapy aplasia, immunosuppressive therapy, corticosteroid therapy (\> 200 mg/d hydrocortisone or equivalent within 4 weeks prior to inclusion) Exclusion Criteria : * Persons under guardianship/guardianship * AME (state medical aid) patient
💊

What it tests

  • Nasopharyngeal swabs and biological collection
📍

Where

1 site
Intensive Care Unit Henri Mondor APHP
Créteil, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy